Surprised By Arvinas’ Slide? What Bears Saw

Arvinas stunned followers with its August 2026 update, reporting Q2 revenue of US$249.7 million and net income of US$169.4 million after a year-earlier quarterly loss. Investors who held Arvinas from the start of the year are down 38.2%, including dividends. If you had put money to work on 1 January, that disconnect between stronger recent results and a weaker share outcome raises a blunt question: Which expectations about Arvinas really deserved that bet?

The useful thing about a Narrative is that the reasoning is checkable: the assumptions sit beside the argument, and together they imply an estimated Fair Value you can disagree with.

The easy part of this move is behind Arvinas. Zero in on 35 high quality undervalued stocks for companies trading below our estimates.

The Two Arvinas Stories Investors Had To Weigh

The shares cost US$11.86 at the start of the period, and anyone looking at Arvinas then had to decide which story felt more convincing.

The bullish Narrative set Fair Value at US$17.44 and hinged on precision therapies. It leaned on Arvinas using its PROTAC platform and assets like ARV-102, ARV-393 and ARV-806 to support revenue growth that was assumed to decline 25.2% a year while profit margin moved to 23.3% and a future P/E of 51.9x.

The bearish view pinned Fair Value at US$7 and focused on concentration risk. It assumed revenue would fall 49.7% annually, with Arvinas still reaching a 20.9% margin on a future P/E of 76.3x, despite dependence on a narrow pipeline and milestone payments.

What The Results Changed For The Arvinas Debate

The headline fact was Arvinas reporting Q2 2026 revenue of US$249.7 million and net income of US$169.4 million. That result, together with a net margin moving from a loss of 273.2% in Q2 2025 to a 67.8% profit margin, clearly leaned toward the bullish case that expected higher profitability, even if it did not settle longer term revenue assumptions.

The useful takeaway for another stock is simple. When a thesis hangs on margin repair, track the reported net margin line each quarter and compare it directly with the margin path the original story assumed, rather than focusing only on top line or share moves.

What Arvinas’ Drop Leaves You Paying For Today

Arvinas trades at US$7.09 after a year to date loss of 38.2% from US$11.86. The selected bullish Narrative still places Fair Value above the current price, tying that view to how its protein degradation platform and licensing deals might support the business over time despite delays and cautious analyst sentiment.

This Narrative leans on Arvinas using its cash runway and partnerships to fund several Phase 1 assets. A buyer today would be assuming that at least some of these early programs progress and attract further deals on terms strong enough to support operations without severely dilutive funding.

"Although Arvinas has secured the first FDA approval of a PROTAC degrader and a Rigel licensing deal that generated US$62.5m of license revenue and a US$50m milestone from Pfizer in Q2 2026, the company now carries a US$52.7m liability for remaining VEPPANU development obligations and does not expect further revenue from the original Pfizer collaboration. This can weigh on future earnings quality and limit upside to net margins."

One Narrative disagrees with today's price. → See where this Narrative says Arvinas should trade

Find Your Own Contrarian Opportunity

This company's disappointment is already part of the story. Your next idea could come from looking where the price and the possibilities still seem far apart. Here are three companies priced below our estimates.

• Company 1 - 45% below our estimate - turns a record backlog of tech heavy projects into modular builds and service contracts.
• Company 2 - 38% below our estimate - leans on a long life reserve base while reassessing higher cost mines in riskier regions.
• Company 3 - 30% below our estimate - ties expanding AI workloads to a growing cloud platform funded by heavier data center spending.

That is three of the list. See the full list of 23 financially solid companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com